GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration 

GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration 

GSK (GlaxoSmithKline) logo and rising stock graph are seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration 

GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration 

A detail view of the exterior of the Unilever headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A London Black Cab passes the Unilever headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

People walk past the Unilever headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A person walks past the Unilever headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay 

GlaxoSmithKline's (GSK) drug, Augmentin, is seen in the COVID-19 Intensive Care Unit (ICU) at the Centre Cardiologique du Nord private hospital in Saint-Denis, near Paris, amid the coronavirus disease pandemic in France, May 4, 2021. REUTERS/Benoit Tessier 

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song 

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song 

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song 

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs 

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs 

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, speaks as U.S. President Donald Trump listens during a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, adjusts his protective face mask after speaking as President Donald Trump holds a coronavirus disease vaccine event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, listens while wearing a protective face mask as President Donald Trump holds a coronavirus disease vaccine event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

U.S. President Donald Trump passes former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, as he removes his face mask to speak during a coronavirus response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

U.S. President Donald Trump looks on as former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, removes his face mask during a coronavirus response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, adjusts his protective face mask after speaking as President Donald Trump holds a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, waits to speak as President Donald Trump holds a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (COVID-19) pandemic, speaks as President Donald Trump listens during a coronavirus disease response event in the Rose Garden at the White House in Washington, U.S., May 15, 2020. REUTERS/Kevin Lamarque 

A tribute to the NHS is seen outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville 

A general view outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville 

A tribute to care workers is seen outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville 

A tribute to the NHS is seen outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville 

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs 

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs 

A box and vials of the drug Shingrix, made by GlaxoSmithKline Pharmaceutical, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey 

A scientist studies cancer cells inside white blood cells through a microscope at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

Scientists look at test tubes containing stem cells at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

Scientists look at test tubes containing stem cells at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A GSK logo is seen on a flag at a GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls 

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS 

Scotland's First Minister Nicola Sturgeon tours GlaxoSmithKline's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS